San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor in the weight loss drug current market in February after revealing promising facts from the mid-phase demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when provided as a weekly injection As well as in March the comp